TScan Therapeutics, Inc. - TCRX STOCK NEWS

TScan Therapeutics has announced the initiation of study start-up activities for its Phase 1 clinical trial involving TSC-100 and TSC-101, following FDA clearance of the investigational new drug (IND) application for TSC-101 targeting hematologic malignancies. This marks the second IND clearance for TScan’s leukemia program, aimed at reducing relapse risks after allogeneic hematopoietic cell transplantation. Preliminary data from the three arms of the trial are expected by the end of 2022.

TScan Therapeutics (TCRX) has identified its lead TCR-T cell therapy candidate, TCR-200-A02, for HPV-positive solid tumors, with an IND submission expected in 2H22. Additionally, TCR-204-C07 targets a novel MAGEA1 epitope, also on track for IND submission. Preclinical results show TCR-200-A02 exhibits strong cytotoxicity against HPV+ cell lines and no off-target activity. The multiplexing of TCRs demonstrates potential for enhanced anti-tumor effectiveness, overcoming tumor antigen heterogeneity. TScan will present further data at a virtual KOL event on May 19, 2022.

TScan Therapeutics (TCRX) announced participation in a virtual fireside chat at the H.C. Wainwright Global Investment Conference scheduled for May 24, 2022, at 7:00 a.m. ET. This event will focus on TCR engineered T cell therapies for cancer treatment. A live webcast will be accessible through the company’s website, and a replay will be available for 30 days afterward. The company specializes in TCR-T therapies targeting hematologic malignancies and solid tumors, leveraging its ImmunoBank of therapeutic TCRs.

TScan Therapeutics (Nasdaq: TCRX) has announced a virtual key opinion leader (KOL) event on May 19, 2022, at 4:30 p.m. ET. The event will discuss highlights from the American Society of Gene & Cell Therapy 25th Annual Meeting and TScan's solid tumor program. Featured speakers include Dr. Kai Wucherpfennig and TScan's executive team. Key topics will include TCR-T therapy candidates TSC-200-A02 and TSC-204-C07, addressing antigen heterogeneity. Registration details and replay options are available on TScan's website.

TScan Therapeutics (TCRX) announced its Q1 2022 financial results, reporting revenue of $3 million, up from $2 million YoY, attributed to its collaboration with Novartis. The company ended the quarter with $140.8 million in cash, sufficient to fund operations into 2024. TScan is set to initiate its Phase 1 umbrella trial for leukemia therapies TSC-100 and TSC-101 in Q2 2022, despite receiving a clinical hold on TSC-101 from the FDA. Future milestones include presenting clinical data by year-end and advancing its solid tumor TCR therapy candidates.

TScan Therapeutics, Inc. (Nasdaq: TCRX) announced it will host a virtual KOL event on May 19, 2022, at 4:30 p.m. ET, discussing key presentations from the ASGCT Annual Meeting held from May 16-19, 2022. Three abstracts were accepted, focusing on innovative TCR-T cell therapies, including TSC-200-A02 for HPV-positive tumors, multiplexed therapies for solid tumors, and a novel TCR-T candidate for head and neck cancer. The company aims to advance its TCR-T candidates, which target multiple antigens to enhance cancer treatment efficacy.

TScan Therapeutics, Inc. (TCRX) has appointed Leiden Dworak, CPA, MBA, as Vice President of Finance, enhancing its financial infrastructure amid clinical advancements. Dworak brings over ten years of financial expertise from roles at AVROBIO and Moderna. His financial planning experience is expected to aid TScan in achieving key development milestones as they progress with their T cell receptor therapies for cancer. TScan is strategically advancing its lead liquid tumor therapies, aiming to prevent relapse post-hematopoietic stem cell transplantation.

TScan Therapeutics (TCRX) has received FDA clearance for its IND application for TSC-100, targeting hematologic malignancies. The Phase 1 trial for its liquid tumor program is set to start in H1 2022, with preliminary data expected in H2 2022. The company anticipates two additional INDs for the TSC-200 series by year-end. As of December 31, 2021, TScan reported cash and equivalents of $161.4 million, which is projected to fund operations into 2024. Revenue surged to $10.1 million for 2021 compared to $1.1 million in 2020, despite a net loss of $48.6 million.

TScan Therapeutics, Inc. (Nasdaq: TCRX) has announced its participation in two major investor conferences. The Cowen 42nd Annual Health Care Conference will feature a virtual discussion on March 9, 2022, at 9:10 a.m. ET. Subsequently, TScan will participate in the Barclays Global Healthcare Conference with a fireside chat on March 16, 2022, at 8:30 a.m. ET in Miami Beach, FL. Webcasts of both sessions will be available on TScan's website, with archived replays accessible for 30 days post-event.